Literature DB >> 23479185

Cyclic variations of bone resorption mediators and markers in the different phases of the menstrual cycle.

Bruno Mozzanega1, Salvatore Gizzo, Daniela Bernardi, Luigi Salmaso, Tito Silvio Patrelli, Roberto Mioni, Livio Finos, Giovanni Battista Nardelli.   

Abstract

Female hormones are very important in regulating bone homeostasis; the drop of estrogen levels occurring at menopause is linked to a dramatic prevalence of bone resorption on formation. Only a small number of studies investigated the relationship between changes in circulating female sex hormones and the markers and mediators of bone homeostasis and they showed conflicting results. To explore such relationships we studied 20 young fertile healthy women, aged between 19 and 32 years. None had received hormone treatment for at least 6 months. We assayed luteinizing hormone, follicle-stimulating hormone, progesterone and 17β-estradiol, as well as the levels of osteoprotegerin (OPG), C-terminal telopeptide of collagen type I (CTx) and RANKL (receptor activator of nuclear factor-B ligand) in samples drawn from every subject at four different times during the menstrual cycle when estrogens are lowest, at the start of the cycle: T 0 (2-4th day); when estrogens are highest, in the pre-ovulatory period: T 14 (12-14th day); when progesterone activity is highest, in the advanced luteal phase: T 26 (24-26th day); and again at the start of the next cycle: T 01 (2-4th day). We observed that CTx levels are highest at the start of the cycle, decreased significantly from T 0 to T 26 (pfwe = 0.0455) and then increased from T 26 to T 01 (pfwe = 0.0415); OPG, on the other hand, which was also highest at the start of the cycle, decreased significantly from T 0 to T 14 (pfwe = 0.02) and then increased, though not significantly, from T 14 to T 01; no variation was observed in RANKL values at any time. We observed inverse correlations between estradiol and OPG levels, which became highly significant at T 01 between estradiol nadir and OPG peak levels (pfw = 0.0095). Furthermore, the increase of estradiol from T 0 to T 14 was negatively correlated with the concomitant decrease of OPG (pfwe = 0.0277), as was the fall of estradiol from T 26 to T 01 with the OPG peak levels, both at T 01 (pfw = 0.0045) and at T 0 (pfwe = 0.0381). We also observed direct correlations between the OPG levels and the variations of progesterone in the preceding intervals, but they never attained statistical significance. We conclude that OPG and CTx fluctuation during the menstrual cycle are likely due to the physiological variations of sex steroids levels.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23479185     DOI: 10.1007/s00774-013-0430-4

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  37 in total

Review 1.  Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases.

Authors:  L C Hofbauer; A E Heufelder
Journal:  J Clin Endocrinol Metab       Date:  2000-07       Impact factor: 5.958

Review 2.  Biology of the basic multicellular unit and the pathophysiology of osteoporosis.

Authors:  Robert L Jilka
Journal:  Med Pediatr Oncol       Date:  2003-09

3.  Physiologic fluctuations of serum estradiol levels influence biochemical markers of bone resorption in young women.

Authors:  A Zittermann; I Schwarz; K Scheld; T Sudhop; H K Berthold; K von Bergmann; H van der Ven; P Stehle
Journal:  J Clin Endocrinol Metab       Date:  2000-01       Impact factor: 5.958

Review 4.  Minireview: the OPG/RANKL/RANK system.

Authors:  S Khosla
Journal:  Endocrinology       Date:  2001-12       Impact factor: 4.736

5.  Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI.

Authors: 
Journal:  JAMA       Date:  1996-11-06       Impact factor: 56.272

6.  The relationship between serum levels of estradiol and osteoprotegerin in patients with anorexia nervosa.

Authors:  Rina Ohwada; Mari Hotta; Kanji Sato; Tamotsu Shibasaki; Kazue Takano
Journal:  Endocr J       Date:  2007-11-12       Impact factor: 2.349

7.  Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts.

Authors:  Volker Viereck; Carsten Gründker; Sabine Blaschke; Britta Niederkleine; Heide Siggelkow; Karl-Heinz Frosch; Dirk Raddatz; Günter Emons; Lorenz C Hofbauer
Journal:  J Clin Endocrinol Metab       Date:  2003-09       Impact factor: 5.958

8.  Transforming growth factor-beta1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells.

Authors:  T Murakami; M Yamamoto; K Ono; M Nishikawa; N Nagata; K Motoyoshi; T Akatsu
Journal:  Biochem Biophys Res Commun       Date:  1998-11-27       Impact factor: 3.575

9.  Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines.

Authors:  L C Hofbauer; C R Dunstan; T C Spelsberg; B L Riggs; S Khosla
Journal:  Biochem Biophys Res Commun       Date:  1998-09-29       Impact factor: 3.575

10.  The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts.

Authors:  S Bord; D C Ireland; S R Beavan; J E Compston
Journal:  Bone       Date:  2003-02       Impact factor: 4.398

View more
  6 in total

1.  Changes of serum sclerostin and Dickkopf-1 levels during the menstrual cycle. A pilot study.

Authors:  Chrysoula G Liakou; George Mastorakos; Konstantinos Makris; Ioannis G Fatouros; Alexandra Avloniti; Helen Marketos; Julia D Antoniou; Antonios Galanos; Ismene Dontas; Demetrios Rizos; Symeon Tournis
Journal:  Endocrine       Date:  2016-09-06       Impact factor: 3.633

2.  Rhythmic Fluctuations in Levels of Liver Enzymes During Menstrual Cycles of Healthy Women and Effects of Body Weight.

Authors:  Chunwei Walter Lai; Sneha Jadhav; Basile Njei; Aijun Ye; Jean Wactawski-Wende; Sunni L Mumford; Enrique F Schisterman; Yaron Rotman
Journal:  Clin Gastroenterol Hepatol       Date:  2019-12-04       Impact factor: 11.382

3.  Menstrual Cycle Related Fluctuations in Circulating Markers of Bone Metabolism at Rest and in Response to Running in Eumenorrheic Females.

Authors:  Anne Guzman; Nigel Kurgan; Sara C Moniz; Seth F McCarthy; Craig Sale; Heather Logan-Sprenger; Kirsty J Elliott-Sale; Tom J Hazell; Panagiota Klentrou
Journal:  Calcif Tissue Int       Date:  2022-04-16       Impact factor: 4.000

Review 4.  Sex Differences in Biological Systems and the Conundrum of Menopause: Potential Commonalities in Post-Menopausal Disease Mechanisms.

Authors:  David A Hart
Journal:  Int J Mol Sci       Date:  2022-04-08       Impact factor: 6.208

5.  Sex Differences in Proatherogenic Cytokine Levels.

Authors:  Stella Bernardi; Barbara Toffoli; Federica Tonon; Morena Francica; Elena Campagnolo; Tommaso Ferretti; Sarah Comar; Fabiola Giudici; Elisabetta Stenner; Bruno Fabris
Journal:  Int J Mol Sci       Date:  2020-05-29       Impact factor: 5.923

Review 6.  The Specificities of Elite Female Athletes: A Multidisciplinary Approach.

Authors:  Carole Castanier; Valérie Bougault; Caroline Teulier; Christelle Jaffré; Sandrine Schiano-Lomoriello; Nancy Vibarel-Rebot; Aude Villemain; Nathalie Rieth; Christine Le-Scanff; Corinne Buisson; Katia Collomp
Journal:  Life (Basel)       Date:  2021-06-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.